Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20 mg OD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients With Clustering Risk Factors.

Trial Profile

Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20 mg OD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients With Clustering Risk Factors.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 31 May 2016

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Cardiovascular disorders; Obesity
  • Focus Therapeutic Use
  • Acronyms CRESCENDO
  • Sponsors Sanofi; Sanofi-Synthelabo
  • Most Recent Events

    • 19 Oct 2012 Planned number of patients changed from 18695 to 20300.
    • 14 Aug 2010 The CRESCENDO study was discontinued early due to concerns by health regulatory authorities about suicide in patients receiving rimonabant.
    • 14 Aug 2010 Results were reported in the Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top